RxDoctor Payments Data

Genevieve Sloboda

Family · Chelmsford, MANPI 1912994195

Payments from drug & device makers

$3,270in general payments, 2019–2025

Across 149 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$685
  • Regeneron Healthcare Solutions, Inc.$567
  • GSK$513
  • Novartis$411
  • Amgen$270
  • Lilly USA, LLC$165
  • plus $660 from 14 others

What the payments were for

  • Food & beverage$3,23099%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,270 in reported general payments places this provider in the 90th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$33,426
Medicare patients
120
Services billed
1,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,600
DuleraMometasone/Formoterol21$7,633
Breo ElliptaFluticasone/Vilanterol11$4,322
Epinephrine14$2,565
Wixela InhubFluticasone Propion/Salmeterol21$1,564
Montelukast Sodium49$889
Ventolin HfaAlbuterol Sulfate13$809
Albuterol Sulfate HfaAlbuterol Sulfate29$653
Ipratropium Bromide24$613
Azelastine Hcl15$475
Fluticasone Propionate20$440
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$158
Prednisone42$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$513$21,92237 claims
MerckDulera$30$7,63321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,320 family providers in Massachusetts.

Other family in Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →